EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang

iNew Medicine · 13.04.2026

DOI: 10.1002/inm3.70052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift iNew Medicine, online erschienen am 13.04.2026. Verfasst von Qianwen Bai und 4 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP), it uniquely dual‐targets the NLRP3 inflammasome and TGF‐β pathway, addressing both inflammation and fibrosis. The trials demonstrated significant slowing of lung function decline, with a manageable safety profile. Critically, its efficacy on background antifibrotic therapy provides robust evidence for viable combination regimens, thereby ushering in a new era of combination therapy for this refractory disease. This marks a paradigm shift, offering renewed hope and paving the way for multi‐targeted treatment strategies, although longer‐term outcomes warrant further study.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Bai, Q., Deng, J., Wang, H., Yao, Y., & Wang, T. (2026). Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy. iNew Medicine. https://doi.org/10.1002/inm3.70052

Vancouver

Bai Q, Deng J, Wang H, Yao Y, Wang T. Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy. iNew Medicine. 2026. doi:10.1002/inm3.70052

BibTeX
@article{Bai2026,
  author = {Bai, Qianwen and Deng, Jia and Wang, Hongquan and Yao, Yao and Wang, Tao},
  title = {Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy},
  journal = {iNew Medicine},
  year = {2026},
  doi = {10.1002/inm3.70052}
}
Kostenlos starten →